W Balduini1, V De Angelis, E Mazzoni, M Cimino. 1. Istituto di Farmacologia e Farmacognosia, Università degli Studi di Urbino, Urbino, Italy. balduini@uniurb.it
Abstract
BACKGROUND AND PURPOSE: Recent studies suggest that statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) not only reduce the incidence of stroke by lowering cholesterol levels but may also exert neuroprotective effects via a mechanism not related to their lipid-lowering effect. Despite the growing body of evidence, however, the neuroprotective effect of statins in stroke is still controversial. Herein, we studied whether a prophylactic administration of simvastatin (Sim) provides significant protection against brain damage, and we sought to determine its long-lasting behavioral consequences in a neonatal model of hypoxia/ischemia. METHODS: Newborn male rats were injected daily from postnatal days 1 to 7 with activated Sim (20 mg/kg) or an equivalent volume of vehicle. On postnatal day 7, the rats were subjected to ligation of the right common carotid artery, followed by 3 hours of hypoxia or by sham operation. The neuroprotective effect of Sim was evaluated after the rats had achieved adulthood by using a battery of behavioral tests and histological analysis. RESULTS: Sim-treated ischemic rats performed the circular water maze, the radial arm maze, and the multiple-choice water maze significantly better than did vehicle-treated ischemic rats. Furthermore, in contrast to the ischemic rats, hypoxia/ischemia-injured rats pretreated with Sim were not hyperactive at weaning and showed less behavioral asymmetry. Consistently, it was found that brain damage was significantly attenuated. CONCLUSIONS: These findings indicate that prophylactic administration of statins may provide a potential neuroprotective strategy leading to an improvement in functional outcome in ischemic stroke. However, toxicity concern must be addressed before these agents can be directed to the asphyxiated fetus or newborn.
BACKGROUND AND PURPOSE: Recent studies suggest that statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) not only reduce the incidence of stroke by lowering cholesterol levels but may also exert neuroprotective effects via a mechanism not related to their lipid-lowering effect. Despite the growing body of evidence, however, the neuroprotective effect of statins in stroke is still controversial. Herein, we studied whether a prophylactic administration of simvastatin (Sim) provides significant protection against brain damage, and we sought to determine its long-lasting behavioral consequences in a neonatal model of hypoxia/ischemia. METHODS: Newborn male rats were injected daily from postnatal days 1 to 7 with activated Sim (20 mg/kg) or an equivalent volume of vehicle. On postnatal day 7, the rats were subjected to ligation of the right common carotid artery, followed by 3 hours of hypoxia or by sham operation. The neuroprotective effect of Sim was evaluated after the rats had achieved adulthood by using a battery of behavioral tests and histological analysis. RESULTS:Sim-treated ischemicrats performed the circular water maze, the radial arm maze, and the multiple-choice water maze significantly better than did vehicle-treated ischemicrats. Furthermore, in contrast to the ischemicrats, hypoxia/ischemia-injured rats pretreated with Sim were not hyperactive at weaning and showed less behavioral asymmetry. Consistently, it was found that brain damage was significantly attenuated. CONCLUSIONS: These findings indicate that prophylactic administration of statins may provide a potential neuroprotective strategy leading to an improvement in functional outcome in ischemic stroke. However, toxicity concern must be addressed before these agents can be directed to the asphyxiated fetus or newborn.
Authors: Nancy Fathali; Robert P Ostrowski; Tim Lekic; Vikram Jadhav; Wenni Tong; Jiping Tang; John H Zhang Journal: Crit Care Med Date: 2010-02 Impact factor: 7.598
Authors: Nancy Fathali; Robert P Ostrowski; Yu Hasegawa; Tim Lekic; Jiping Tang; John H Zhang Journal: Transl Stroke Res Date: 2013-04 Impact factor: 6.829
Authors: Xiaodi Chen; Dawei Song; Sakura Nakada; Joseph Qiu; Karin Iwamoto; Ray H Chen; Yow-Pin Lim; William J Jusko; Barbara S Stonestreet Journal: Curr Pharm Des Date: 2020 Impact factor: 3.116
Authors: Xiaodi Chen; Sakura Nakada; John E Donahue; Ray H Chen; Richard Tucker; Joseph Qiu; Yow-Pin Lim; Edward G Stopa; Barbara S Stonestreet Journal: Exp Neurol Date: 2019-03-23 Impact factor: 5.330
Authors: Mitchell S V Elkind; Ralph L Sacco; Robert B Macarthur; Ellinor Peerschke; Greg Neils; Howard Andrews; Joshua Stillman; Tania Corporan; Dana Leifer; Rui Liu; Ken Cheung Journal: Cerebrovasc Dis Date: 2009-07-16 Impact factor: 2.762
Authors: Mitchell S V Elkind; Ralph L Sacco; Robert B MacArthur; Daniel J Fink; Ellinor Peerschke; Howard Andrews; Greg Neils; Josh Stillman; Tania Corporan; Dana Leifer; Ken Cheung Journal: Int J Stroke Date: 2008-08 Impact factor: 5.266
Authors: Henrik Hagberg; Carina Mallard; Donna M Ferriero; Susan J Vannucci; Steven W Levison; Zinaida S Vexler; Pierre Gressens Journal: Nat Rev Neurol Date: 2015-02-17 Impact factor: 42.937